Ascletis files two FDA INDs for once-monthly obesity drugs targeting amylin, GLP-1R, and GIPR
Ascletis files two FDA INDs for once-monthly obesity drugs targeting amylin, GLP-1R, and GIPR
July 06, 2026 | 14:23(0) user say
Ascletis submitted two IND applications to the US FDA for obesity treatments: ASC36, a once-monthly peptide amylin receptor agonist, and ASC36_35 FDC, a potentially first-in-class co-formulation hitting three validated targets — amylin receptor, GLP-1R, and GIPR — in a single monthly injection.
HONG KONG, July 6, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today recent submissions of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for ASC36, a once-monthly to once-quarterly next-generation peptide amylin receptor agonist and ASC36_35 FDC, a once-monthly injection co-formulation of ASC36 plus peptide GLP-1R/GIPR agonist ASC35, for the treatment of obesity
“Eloralintide in combination with tirzepatide recently demonstrated 29.0% <a href="https://healthylife7.com/3-dietitians-agree-the-best-breakfast-for-weight-loss-is-a-spinach-egg-scramble/" title="3 Dietitians Agree: The Best Breakfast for Weight Loss is a Spinach-Egg Scramble”>weight loss at week 32[1]. However, two separate weekly injections are required; one for eloralintide and one for tirzepatide. In contrast, ASC36_35 FDC, a potentially first-in-class subcutaneous (SQ) injection co-formulation targeting amylin receptor, GLP-1R and GIPR, requires only one monthly injection,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “Equally exciting, ASC36_35 FDC demonstrated approximately 51% greater relative body weight reduction compared to the co-administration of eloralintide and tirzepatide in a head-to-head diet-induced obese (DIO) rat study. These animal models are highly predictive of human efficacy.”
Both ASC36 and ASC35 were discovered in-house utilizing Ascletis’ Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD). Both ASC36 once-monthly to once-quarterly formulation and ASC36_35 FDC once-monthly co-formulation are Self-Assembling Lipid Depot (SALD) formulations, developed in-house utilizing Ascletis’ Ultra-Long-Acting Platform (ULAP) technology
In head-to-head non-human primate (NHP) studies, ASC36 SALD formulation demonstrated approximately 6-fold longer observed half-life than eloralintide, supporting once-monthly to once-quarterly SQ administration in humans. In NHP studies, ASC36_35 FDC SALD co-formulation demonstrated long observed half-lives for both ASC36 and ASC35, supporting once-monthly SQ administration in humans
Preclinical studies have established the superior efficacy of ASC36 injection and ASC36_35 FDC injection co-formulation. In head-to-head DIO rat studies, which are highly predictive of human efficacy, ASC36 monotherapy, targeting amylin receptor, demonstrated approximately 91% and 32% greater relative body weight reduction compared to petrelintide and eloralintide monotherapies, respectively. In head-to-head DIO rat studies, the ASC36_35 co-formulation, targeting three targets of amylin receptor, GLP-1R and GIPR, demonstrated approximately 51% greater relative body weight reduction compared to the co-administration of eloralintide and tirzepatide.
Both ASC36 injection formulation and ASC36_35 FDC injection co-formulation exhibit excellent chemical and physical stability with no aggregation or precipitation caused by fibrillation at neutral pH
Two IND submissions for ASC36 once-monthly injection and ASC36_35 once-monthly injection co-formulation build upon the recent milestone achieved by ASC35 once-monthly SALD formulation. In June 2026, Ascletis announced U.S. FDA IND clearance to initiate a Phase I clinical trial for ASC35 as a once-monthly SQ treatment for obesity (Press Release), highlighting the Company’s robust clinical execution and the potential of its ULAP technology
[1] Eli Lilly and Company. Safety, tolerability, pharmacokinetics and pharmacodynamics of eloralintide and tirzepatide co-administered as once-weekly subcutaneous injections [Abstract accepted for presentation at EASD 2026]
For more information, please visit www.ascletis.com
By PR Newswire
Ascletis Pharma Inc
Tag:AscletisAscletis Pharma Incobesity drugs
Latest News
IvyBears crosses 2.5 million subscribers and 40 million views in global kids content push
Chongqing financial summit ties capital to innovation industries in economic pivot
Vantage lets eligible clients trade Gold CFDs around the clock including weekends
Latest News
Malaysia’s first digital Islamic bank AEON adds term and working capital financing products
Coca-Cola rolls into all Subway Hong Kong and Macau outlets from July under new deal
DKSH takes on Lilly drug sales and distribution across Hong Kong and Macau markets
NTU’s Team Helios wins Asian Hackathon for Green Future 2026 in Hanoi over 439 teams
Mobile Version
